Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Feb;77(2):405–415. doi: 10.1172/JCI112318

Isolation and study of an acquired inhibitor of human coagulation factor V.

M E Nesheim, W L Nichols, T L Cole, J G Houston, R B Schenk, K G Mann, E J Bowie
PMCID: PMC423360  PMID: 3944265

Abstract

A coagulation Factor V inhibitor developed in a man 75 yr of age in association with an anaplastic malignancy and drug treatment (including the aminoglycoside antibiotic, gentamicin). The patient did not bleed abnormally, despite both surgical challenge and plasma Factor V activity of less than 1%. The inhibited plasma had grossly prolonged prothrombin and activated partial thromboplastin times, but a normal thrombin time. Mixing studies indicated progressive coagulation inhibition with normal plasma, but not with Factor V-deficient plasma, and reversal of coagulation inhibition by the addition of bovine Factor V to the patient's plasma. 1 ml of patient plasma inhibited the Factor V activity of 90 ml of normal human plasma. The inhibitor was isolated by sequential affinity chromatography on protein A-Sepharose and Factor V-Sepharose. The IgG isolate markedly inhibits the activity of prothrombinase assembled from purified Factors Xa and Va, calcium ion, and phospholipid vesicles, and partially inhibits prothrombinase assembled from purified Factor Xa, calcium ion, and normal platelets. The Factor V of platelets, however, appears relatively inaccessible to the antibody, inasmuch as platelets isolated from whole blood supplemented for 8 h with the antibody functioned normally with respect to platelet Factor V-mediated prothrombinase function. The absence of obvious hemorrhagic difficulties in the patient, the total inhibition of plasma Factor V by the inhibitor, and the apparent inaccessibility of platelet Factor V to the inhibitor specifically implicate platelet Factor V in the maintenance of hemostasis.

Full text

PDF
405

Images in this article

410Image
on p.410
410Image
on p.410
410Image
on p.410

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe T., Kazama M., Itokazu K., Kinoshita T., Ogushi T., Tahara C., Fukui H. [A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA--with bibliographic review (author's transl)]. Rinsho Ketsueki. 1980 Nov;21(11):1664–1673. [PubMed] [Google Scholar]
  2. BORCHGREVINK C. F., OWREN P. A. The hemostatic effect of normal platelets in hemophilia and factor V deficiency. The importance of clotting factors adsorbed on platelets for normal hemostasis. Acta Med Scand. 1961 Sep;170:375–383. doi: 10.1111/j.0954-6820.1961.tb00250.x. [DOI] [PubMed] [Google Scholar]
  3. Bajaj S. P., Rapaport S. I., Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem. 1981;11(4):397–412. doi: 10.1080/00327488108065531. [DOI] [PubMed] [Google Scholar]
  4. Barenholz Y., Gibbes D., Litman B. J., Goll J., Thompson T. E., Carlson R. D. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry. 1977 Jun 14;16(12):2806–2810. doi: 10.1021/bi00631a035. [DOI] [PubMed] [Google Scholar]
  5. Bryning K., Leslie J. Factor V inhibitor and bullous pemphigoid. Br Med J. 1977 Sep 10;2(6088):677–678. doi: 10.1136/bmj.2.6088.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chediak J., Ashenhurst J. B., Garlick I., Desser R. K. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions. Blood. 1980 Nov;56(5):835–841. [PubMed] [Google Scholar]
  7. Chiu H. C., Rao A. K., Beckett C., Colman R. W. Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood. 1985 Apr;65(4):810–818. [PubMed] [Google Scholar]
  8. Chong L. L., Wong Y. C. A case of factor V inhibitor. Am J Hematol. 1985 Aug;19(4):395–399. doi: 10.1002/ajh.2830190410. [DOI] [PubMed] [Google Scholar]
  9. Church W. R., Jernigan R. L., Toole J., Hewick R. M., Knopf J., Knutson G. J., Nesheim M. E., Mann K. G., Fass D. N. Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins. Proc Natl Acad Sci U S A. 1984 Nov;81(22):6934–6937. doi: 10.1073/pnas.81.22.6934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coots M. C., Muhleman A. F., Glueck H. I. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol. 1978;4(2):193–206. doi: 10.1002/ajh.2830040212. [DOI] [PubMed] [Google Scholar]
  11. Crowell E. B., Jr Observations on a factor-V inhibitor. Br J Haematol. 1975 Mar;29(3):397–404. doi: 10.1111/j.1365-2141.1975.tb01837.x. [DOI] [PubMed] [Google Scholar]
  12. Davie E. W., Fujikawa K. Basic mechanisms in blood coagulation. Annu Rev Biochem. 1975;44:799–829. doi: 10.1146/annurev.bi.44.070175.004055. [DOI] [PubMed] [Google Scholar]
  13. FERGUSON J. H., JOHNSTON C. L., Jr, HOWELL D. A. A circulation inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood. 1958 Apr;13(4):382–397. [PubMed] [Google Scholar]
  14. Feinstein D. I. Acquired inhibitors of factor V. Thromb Haemost. 1978 Jun 30;39(3):663–674. [PubMed] [Google Scholar]
  15. Feinstein D. I., Rapaport S. I. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972;1:75–95. [PubMed] [Google Scholar]
  16. Feinstein D. I., Rapaport S. I., Chong M. M. Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med. 1973 Mar;78(3):385–388. doi: 10.7326/0003-4819-78-3-385. [DOI] [PubMed] [Google Scholar]
  17. Feinstein D. I., Rapaport S. I., McGehee W. G., Patch M. J. Factor V anticoagulants: clinical, biochemical, and immunological observations. J Clin Invest. 1970 Aug;49(8):1578–1588. doi: 10.1172/JCI106375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fratantoni J. C., Hilgartner M., Nachman R. L. Nature of the defect in congenital factor V deficiency: study in a patient with an acquired circulating anticoagulant. Blood. 1972 Jun;39(6):751–758. [PubMed] [Google Scholar]
  19. Grace C. S., Wolf P. Proceedings: A high titre circulating inhibitor of human factor V: clinical, biochemical and immunological features and its treatment by plasmapheresis. Thromb Diath Haemorrh. 1975 Sep 30;34(1):322–322. [PubMed] [Google Scholar]
  20. Handley D. A., Duncan B. M. A circulating anticoagulant specific for factor V. Pathology. 1969 Oct;1(4):265–272. doi: 10.3109/00313026909071305. [DOI] [PubMed] [Google Scholar]
  21. Hoyer L. W., Gawryl M. S., de la Fuente B. Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res. 1984;150:73–85. [PubMed] [Google Scholar]
  22. Hurtubise P. E., Coots M. C., Jacob D. J., Muhleman A. F., Glueck H. I. A monoclonal IgG4 (lambda) with factor V inhibitory activity. J Immunol. 1979 May;122(5):2119–2121. [PubMed] [Google Scholar]
  23. Jobard J., Pourcher N., Gratecos N., Bayle J. Syndrome hémorragique dû à un anticoagulant circulant antifacteur V. Correction par tra transfusion de plasma frais congelé et par échanges plasmatiques. Presse Med. 1983 Jun 11;12(25):1606–1606. [PubMed] [Google Scholar]
  24. Katzmann J. A., Nesheim M. E., Hibbard L. S., Mann K. G. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A. 1981 Jan;78(1):162–166. doi: 10.1073/pnas.78.1.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kuto M., Izuchi Y., Deguchi K., Morito T., Lee C., Wada H. An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Nihon Ketsueki Gakkai Zasshi. 1981 Jul;44(4):938–950. [PubMed] [Google Scholar]
  26. Lane T. A., Shapiro S. S., Burka E. R. Factor V antibody and disseminated intravascular coagulation. Ann Intern Med. 1978 Aug;89(2):182–185. doi: 10.7326/0003-4819-89-2-182. [DOI] [PubMed] [Google Scholar]
  27. Lerolle D., Dreyer-Dufer C., Allain J. P. Anticoagulant circulant spécifique du facteur V. Etude clinique, biologique et thérapeutique. Nouv Presse Med. 1981 Apr 25;10(18):1483–1487. [PubMed] [Google Scholar]
  28. Lopez V., Pflugshaupt R., Bütler R. A specific inhibitor of human clotting factor V. Acta Haematol. 1968;40(5):275–285. doi: 10.1159/000208915. [DOI] [PubMed] [Google Scholar]
  29. Lust A., Bellon A. A circulating anticoagulant against factor V. Acta Clin Belg. 1978;33(1):62–65. doi: 10.1080/22953337.1978.11718618. [DOI] [PubMed] [Google Scholar]
  30. Mann K. G. Prothrombin. Methods Enzymol. 1976;45:123–156. doi: 10.1016/s0076-6879(76)45016-4. [DOI] [PubMed] [Google Scholar]
  31. Miletich J. P., Jackson C. M., Majerus P. W. Properties of the factor Xa binding site on human platelets. J Biol Chem. 1978 Oct 10;253(19):6908–6916. [PubMed] [Google Scholar]
  32. Miletich J. P., Majerus D. W., Majerus P. W. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest. 1978 Oct;62(4):824–831. doi: 10.1172/JCI109194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mustard J. F., Perry D. W., Ardlie N. G., Packham M. A. Preparation of suspensions of washed platelets from humans. Br J Haematol. 1972 Feb;22(2):193–204. doi: 10.1111/j.1365-2141.1972.tb08800.x. [DOI] [PubMed] [Google Scholar]
  34. Nesheim M. E., Eid S., Mann K. G. Assembly of the prothrombinase complex in the absence of prothrombin. J Biol Chem. 1981 Oct 10;256(19):9874–9882. [PubMed] [Google Scholar]
  35. Nesheim M. E., Katzmann J. A., Tracy P. B., Mann K. G. Factor V. Methods Enzymol. 1981;80(Pt 100):249–274. doi: 10.1016/s0076-6879(81)80023-7. [DOI] [PubMed] [Google Scholar]
  36. Nesheim M. E., Kettner C., Shaw E., Mann K. G. Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem. 1981 Jul 10;256(13):6537–6540. [PubMed] [Google Scholar]
  37. Nesheim M. E., Prendergast F. G., Mann K. G. Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. Biochemistry. 1979 Mar 20;18(6):996–1003. doi: 10.1021/bi00573a010. [DOI] [PubMed] [Google Scholar]
  38. Nesheim M. E. Quantitative features of the structure, function and modulation of prothrombinase. Surv Synth Pathol Res. 1984;3(3):219–232. doi: 10.1159/000156927. [DOI] [PubMed] [Google Scholar]
  39. Nesheim M. E., Taswell J. B., Mann K. G. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem. 1979 Nov 10;254(21):10952–10962. [PubMed] [Google Scholar]
  40. Nesheim M. E., Tracy R. P., Mann K. G. "Clotspeed," a mathematical simulation of the functional properties of prothrombinase. J Biol Chem. 1984 Feb 10;259(3):1447–1453. [PubMed] [Google Scholar]
  41. Neville D. M., Jr Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem. 1971 Oct 25;246(20):6328–6334. [PubMed] [Google Scholar]
  42. Nilsson I. M., Hedner U., Ekberg M., Denneberg T. A circulating anticoagulant against factor V. Acta Med Scand. 1974 Jan-Feb;195(1-2):73–77. doi: 10.1111/j.0954-6820.1974.tb08099.x. [DOI] [PubMed] [Google Scholar]
  43. Onuora C. A., Lindenbaum J., Nossel H. L. Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci. 1973 May;265(5):407–417. doi: 10.1097/00000441-197305000-00008. [DOI] [PubMed] [Google Scholar]
  44. Stenbjerg S., Husted S., Mygind K. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Scand J Haematol. 1975 May;14(4):280–285. doi: 10.1111/j.1600-0609.1975.tb02428.x. [DOI] [PubMed] [Google Scholar]
  45. Takase T., Fujimura Y., Mikami S., Fukui H., Fukui H., Tsujii T., Hashimoto A. [Factor V inhibitor developing in a patient with pulmonary tuberculosis (author's transl)]. Rinsho Ketsueki. 1980 Jul;21(7):1038–1046. [PubMed] [Google Scholar]
  46. Tracy P. B., Eide L. L., Bowie E. J., Mann K. G. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982 Jul;60(1):59–63. [PubMed] [Google Scholar]
  47. Tracy P. B., Giles A. R., Mann K. G., Eide L. L., Hoogendoorn H., Rivard G. E. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest. 1984 Oct;74(4):1221–1228. doi: 10.1172/JCI111531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tracy P. B., Nesheim M. E., Mann K. G. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem. 1981 Jan 25;256(2):743–751. [PubMed] [Google Scholar]
  49. Triplett D. A., Brandt J. T., Kaczor D., Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983 Jun;79(6):678–682. doi: 10.1093/ajcp/79.6.678. [DOI] [PubMed] [Google Scholar]
  50. Vickars L. M., Coupland R. W., Naiman S. C. The response of an acquired Factor V inhibitor to activated Factor IX concentrate. Transfusion. 1985 Jan-Feb;25(1):51–53. doi: 10.1046/j.1537-2995.1985.25185116503.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES